MaxCyteMXCT +3.54%62 Market Cap is $140.87 Mil as of Jun. 26, 2026. GuruFocus rates MXCT with a GF Score™ of 62/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 866 Medical Devices & Instruments companies, MaxCyte ranks better than 51.62% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MaxCyte's share price for the quarter that ended in Mar. 2026 was $0.7025. MaxCyte's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 107.12 Mil. Therefore, MaxCyte's market cap for the quarter that ended in Mar. 2026 was $75.25 Mil.
MaxCyte's quarterly market cap
declined
from Sep. 2025 ($168.50 Mil) to Dec. 2025 ($165.52 Mil) and
declined
from Dec. 2025 ($165.52 Mil) to Mar. 2026 ($75.25 Mil).
MaxCyte's annual market cap
declined
from Dec. 2023 ($488.62 Mil) to Dec. 2024 ($439.76 Mil) and
declined
from Dec. 2024 ($439.76 Mil) to Dec. 2025 ($165.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MaxCyte's Enterprise Value for Today is $51.50 Mil.
MaxCyte (NAS:MXCT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
MaxCyte Market Cap Related Terms
MaxCyte Market Cap Historical Data
* Premium members only.
The historical data trend for MaxCyte's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Market Cap distribution charts can be found below:
* The bar in red indicates where MaxCyte's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MaxCyte's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte (MXCT) has a Market Cap of $140.87 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MaxCyte and its competitors. According to the industry distribution chart, MaxCyte ranks #419 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 48.4%.
Is MaxCyte's Market Cap too high?
MaxCyte's current Market Cap is $140.87 Mil. The Medical Devices & Instruments industry median Market Cap is 121.29. MaxCyte's value of $140.87 Mil is 16.1% above this industry median. Based on the distribution chart, MaxCyte ranks #419 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Market Cap compare to RCEL and NNOX?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #419 out of 866 companies for Market Cap. This puts MaxCyte in the upper half of its industry. The industry median Market Cap is 121.29. MaxCyte's value of $140.87 Mil is 16.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Market Cap of $140.87 Mil is 16.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Market Cap is $140.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.32 — trading 48.8% below its estimated fair value. The current Market Cap is $140.87 Mil and 16.1% above the Medical Devices & Instruments industry median of 121.29. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MaxCyte (MXCT), the current Market Cap is $140.87 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.32 is trading 48.8% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Market Cap: $140.87 Mil
GF Value™: $2.57 vs. price of $1.32 (48.8% below fair value)
Industry Position: 16.1% above the Medical Devices & Instruments median (#419 of 866)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
